Navigation Links
Pancreatic in Medical Technology

ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer

november is Pancreatic Cancer Awareness Month Oak Brook, Ill., Nov. 24 /PRNewswire-USNewswire/ -- The American Society for Gastrointestinal Endoscopy (ASGE) and the Pancreatic Cancer Action Network are teaming up this November to raise awareness about pancreatic cancer, educating patient...

New Cancer Treatment Shrinks Pancreatic Tumor

NASHVILLE, Tenn., Nov. 24 /PRNewswire/ -- A new cancer treatment is realizing outstanding results against pancreatic cancer. Following five weeks of treatment, a patient's large, stage 4 tumor was reduced in size by 70%. After seven more weeks of treatment, it no longer could be definitely identif...

RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors

- 82% of patients with pancreatic neuroendocrine tumors (NET) experienced clinical benefit when treated with daily RAD001 and monthly Sandostatin LAR Depot - 77% of patients with pancreatic NET experienced clinical benefit when treated with ...

Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer

EAST SETAUKET, N.Y., Aug. 8 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) announced today that lead compounds from each of two different types of drugs being developed as potential treatment for specific types of brain cancers have activity against hum...

Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma

CHICAGO and REGENSBURG, Germany, June 2 /PRNewswire/ -- The TGF-beta 2 inhibitor AP 12009, developed by Antisense Pharma, reveals very good safety and tolerability in the systemic treatment of pancreatic carcinoma, malignant melanoma and colorectal carcinoma. AP 12009, administered intravenous...

Patients with Pancreatic Cancer Can Benefit From Avastin(R) Plus Tarceva(R)

- Results Confirm Previously Demonstrated Survival Advantages of Tarceva in This Difficult-to-Treat Disease - ABSTRACT No: 4507 BASEL, Switzerland, May 31 /PRNewswire/ -- Adding Avastin (bevacizumab) to a combination of Tarceva (erlotinib) and chemothe...

Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer

Second Phase Opens With Higher Dose Regimens SAN MARINO, Calif., April 21 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today that Interim Analysis of an on-going Phase I/II study of Rexin-G for pancreatic cancer confirmed Rexin-G's anti-tumor activity with no majo...

Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging

WALTHAM, Mass., April 16 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN ) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the development program for RG1068, synthetic human secretin, to improve the assessment of pancreatic ...

Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data

NEW BRUNSWICK, N.J., April 15 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT ) announced today further details of Dr. Raghavendra Mirmira's preclinical pancreatic islet cell research that was funded by the Company. Using a small interfering RNA (s...

Senesco's Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences

NEW BRUNSWICK, N.J., April 2, 2008 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT ) announced today that Dr. Raghavendra Mirmira, one of the Company's funded researchers, will be presenting his findings regarding preclinical pancreatic islet cell ...

Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging

WALTHAM, Mass., March 26 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN ) announced today that the Company has initiated a Phase 3 clinical trial to evaluate the use of RG1068, synthetic human secretin, to improve the assessment of pancreatic duct structures by magnetic resonanc...

Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer

SOUTH SAN FRANCISCO, Calif., March 13 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the discovery and development of monoclonal antibody therapeutics (MAbs) for cancer, today announced that it has initiated a Phase 2 study of RAV12, its lead clinical product,...

Mayo Clinic Study Finds Further Association Between Diabetes and Pancreatic Cancer

Study's authors recruit patients for a clinical trial, another step in this ongoing research ROCHESTER, Minn., Jan. 23 /PRNewswire-USNewswire/ -- A new Mayo Clinic study found that 40 percent of pancreatic cancer patients are diagnosed with diabetes prior to their pancreatic cancer diagnos...

EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer

Multi-Center Study to Focus on Advanced Cancer Patients ROCKVILLE, Md., Dec. 4 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has c...

Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer

BOULDER, Colo., Oct. 3 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (Nasdaq: TPPH ) announced today that it has initiated a Phase 2 open- label, multi-center study of TPI 287 in patients with advanced pancreatic cancer. This is the second Phase 2 trial exploring the activity of TP...

Protein Found to Shield Pancreatic Cancer Cells from Self-Destruction

HOUSTON, March 20, 2007 - An overexpressed protein protects human pancreatic cancer cells from being forced to devour themselves, removing one of the body's natural defenses against out-of-control cell growth, researchers at The University of Texas M. D. Anderson Cancer Center report in the March...

Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer

NEW YORK, April 10, 2007 /PRNewswire-FirstCall/ -- ImClone Systems Incorporated and Bristol-Myers Squibb Company today announced that a Phase III study of ERBITUX(R) (Cetuximab) plus gemcitabine (a chemotherapy) in patients with locally advanced unresectable or metastatic pancreatic cancer did not...

OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study Published in the Journal of Clinical Oncology Showed Survival Improvement in Patients with Pancreatic Cancer

MELVILLE, N.Y.--(BUSINESS WIRE)--Apr 25, 2007 - OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that results published yesterday in the Journal of Clinical Oncology show that adding Tarceva(R) (erlotinib) to gemcitabine chemotherapy significantly improves survival when administered as firs...

New Data Show Pfizer's Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy

CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Pfizer announced today that axitinib (AG-013736), an investigational oral, selective inhibitor of VEGFR 1, 2,3 (vascular endothelial growth factor receptors 1, 2, 3) combined with gemcitabine showed a trend towards prolonged overall survival (OS) in patients ...

Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer

SOUTH SAN FRANCISCO, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announced follow-up data from a Phase 2 clinical trial of GVAX immunotherapy for pancreatic cancer which was conducted by the Johns Hopkins Sidney Kimmel Cancer Center. The trial enrolled 60 patients with...

Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients

PHILADELPHIA, July 3, 2007-- – The appearance of a rash in cancer patients treated with erlotinib (Tarceva) is strongly associated with longer survival, according to researchers from the drug’s developer, OSI Pharmaceuticals, Inc. This is not the first time that rash has been associate...

Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting System's Success in Mouse Model Reported in Cancer Cell

HOUSTON, July 9, 2007 - A molecularly engineered therapy selectively embeds a gene in pancreatic cancer that shrinks or eradicates tumors, inhibits metastasis, and prolongs survival with virtually no toxicity, researchers from The University of Texas M. D. Anderson Cancer Center report in the Jul...

Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership

... partnership between JDRF and GNF aims to deliver a succession of drug candidates to the clinic over the next four years. The initial focus will be on pancreatic beta cell regeneration and survival, to restore beta cell function in diabetes. The program builds on current JDRF funding at GNF that has resulted in...

Study Suggests Vitamin D Screening and Appropriate Supplementation Indicated for All Cancer Patients

...ean age at presentation was 55.7 years (SD = 10.2) and the most common cancer types were lung (133, 18%), breast (131, 17.8%), colorectal (97, 13.2%), pancreatic (86, 11.7%), prostate (44, 6%) and ovarian (38, 5.2%). Before the study, the researchers hypothesized that malnutrition could contribute to vita...

Researchers Say More Aggressive Vitamin D Supplementation Needed in Obese Cancer Patients

...ears (SD = 10.2). The mean BMI was 27.9 kg/m2 (SD = 6.7). The most common cancers were lung (134, 18.1%), breast (131, 17.7%), colorectal (97, 13.1%), pancreatic (86, 11.6%), prostate (45, 6.1%) and ovarian (39, 5.3%). The mean vitamin D (serum 25(OH)D) was 21.9 ng/ml (SD = 13.5). The study concluded that ...

Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines

...ACE, heart attack and stroke) was statistically significant. RECORD showed no evidence of an increase in malignancies. There were fewer events of pancreatic cancer in patients taking Avandia although the numbers were small. "RECORD provides important and reassuring information about Avandia for physi...

TNFerade(TM) Phase III Data Presented at ASCO

...Call/ -- Overall survival data in locally advanced pancreatic cancer patients treated with TNFerade(TM) in GenVec's ongoing Phase III pancreatic Cancer Clinical Trial with TNFerade(TM) (PACT) wer...h Chemoradiation in Patients with Locally Advanced pancreatic Cancer: Interim Analysis of Overall Survival," rep...

Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer

...idates are being developed for the treatment of rheumatoid arthritis, multiple sclerosis and other autoimmune diseases as well as for the treatment of pancreatic and metastatic breast cancer. Plexxikon's proprietary Scaffold-Based Drug Discovery(TM) platform integrates multiple state-of-the-art technologie...

Stand Up To Cancer Awards $73.6 Million for Novel, Groundbreaking Cancer Research

... "Cutting off the Fuel Supply: A New Approach to the Treatment of pancreatic Cancer" / Leaders: Craig B. Thompson, M.D., Director, Abramson Cancer Cen...he further development of proposals, where needed, and in two instances (in pancreatic cancer and breast cancer) where two teams proposed related approaches to re...

BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting

...l data generated to date, coupled with a benign side effect profile. Previous clinical trials have enrolled patients with breast cancer, melanoma, and pancreatic cancer in addition to head and neck cancer, and clinical activity has been observed in each of these cancer types. The Company recently commenced a Ph...

New Report Shows Record Number of Medicines in Development to Treat Leading Causes of Cancer

...or prostate cancer, which this year is expected to kill 28,000 American men. Additional medicines target brain cancer, kidney cancer, ovarian cancer, pancreatic cancer, skin cancer, and others. The medicines represent many cutting-edge approaches, including a drug that delivers a synthetic version of a su...

New Cancer Treatment Stops Aggressive Sarcomas

... the great majority of patients so far." The protocol also is offered for qualifying patients with mesothelioma, colon cancer, renal (kidney) cancer, pancreatic cancer and melanoma. This investigative treatment is a combination of lovastatin, typically used as a cholesterol lowering agent, and interferon....

Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration

... exploring the use of REOLYSIN(R) in combination with chemotherapy for various cancer indications. These indications are expected to include melanoma, pancreatic cancer, squamous cell lung, liver and K-RAS mutated colorectal cancers in combination with standard chemotherapeutics. This research program is in add...

New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors

...rse mixture of tumors originating from the interface between the endocrine (hormonal) system and the nervous system, and includes carcinoid tumors and pancreatic NETs. Treatment options for patients with NETs are limited, with surgery being the only chance for cure. When the tumor is inoperable, the objectives ...

Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals

...efficiently promote insulin release by beta cells in response to elevated blood glucose levels. In addition, the GDIR is expressed in cells other than pancreatic beta cells, such as endocrine cells in the gastrointestinal tract, and in preclinical studies the GDIR stimulates the release of GLP and GIP, two incr...

Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer

...t (165), ovarian (143), stomach (98), rectal (87), pancreatic (53), head and neck (36), and other cancers (54) w...and 8.8 percent in the placebo arm). Patients with pancreatic cancer also experienced a high overall rate of thr...ortionately higher incidence of events in lung and pancreatic cancer patients, further studies should focus on p...

GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting

...eloping novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. Additional clinical trials are in progress in rectal cancer, head and neck cancer, and melanoma. GenVec also uses its proprietary adenovector ...

Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483

...-27483 inhibits tumor growth in an animal model of pancreatic cancer. In previous animal studies, the company ha...nical studies have shown that approximately 90% of pancreatic cancers express tissue factor. Accordingly, we are...9 to evaluate PCI-27483's effects in patients with pancreatic cancer." About Factor VII and PCI-27483 ...

FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain

...injury, intracranial lesions, or other sources of preexisting increased intracranial pressure. Tapentadol should be used with caution in patients with pancreatic or biliary tract disease, and moderate hepatic impairment. Because elderly patients are more likely to have decreased renal and hepatic function, cons...

PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients

...ients had nonsense-mutation CF, pathological lung infection, and CF-induced pancreatic insufficiency. In a cross-over design testing 14 days of PTC124 at two dose...e lung function. In addition, the majority of cystic fibrosis patients take pancreatic enzyme supplements to assist with food absorption in digestion. There is a ...
Other Tags
(Date:10/16/2014)... the human body. Battles are won, lost or ... this stalemate—known as tumor dormancy—can last up to ... that is poorly understood. , A new ... Torquato, a Professor of Chemistry at Princeton University, ... and the switch to a malignant state. Published ...
(Date:10/16/2014)... are anything but sustainable: environmental damage to soil ... increasingly evident. Despite their disadvantages, however, monocultures remain ... the sole possibility of achieving higher yields in ... an ecology professor at the University of Zurich, ... forestry. After all, a new study carried out ...
(Date:10/15/2014)... WASHINGTON, N.Y. , Oct. 15, 2014 /PRNewswire/ ... technology solutions for home and community-based care, today ... benefits of implementing Sandata,s Santrax® Electronic Visit Verification™ ... Care Services is a home health company founded ... Texas . The ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Sandata Announces Case Study with Quality Care Services, Inc. 2
(Date:10/22/2014)... On October 22, CBS will air ... diseases both fictional and real. The Charles E ... committed to advocacy and philanthropy in the battle against ... opportunity to impart truth and clarity about this misunderstood ... many misconceptions about Morgellons Disease (MD) and ...
(Date:10/22/2014)... Amy Norton HealthDay Reporter ... remain riveted on the three Ebola cases in Dallas. But, ... health threat to Americans. President Barack Obama on Friday ... the virus, which has infected two Dallas nurses who cared ... at Texas Health Presbyterian Hospital. But the U.S. cases ...
(Date:10/22/2014)... 22, 2014 Hay House is pleased to ... and Upgrade Your Life (Paperback; $10.82) written by the highly ... Recovery. This book is meant to help readers of ... of recovery. , Recovery 2.0 is not the average ... 2.0 is a guide for what comes next. ...
(Date:10/22/2014)... 2014 Healthcare professionals who are ... education at home or on-the-go via laptops, tablets ... brand new, premium Seminar-on-Demand CE courses. The new ... 2,000 hours of CE course offerings, ... experience. With such a diverse library, there’s something ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Richard Carlson, ... an industry leader with over 25 years experience. ... leader in the areas related to EDI, B2B Commerce, ... is an Editorial Advisory Board member for Pharmaceutical Commerce ... Blue Fin Group is a management and technology ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2
Other Contents